● Recruiting

Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate Cancer

Condition: Metastatic Hormone-sensitive Prostate Cancer (mHSPC) · Sponsor: Amgen

PhasePhase 1

Planned participants60

Who can joinMale, 18 Years to no upper limit

Healthy volunteersNo

About this study

The main objective of the trial is to evaluate the safety and tolerability of xaluritamig in combination with darolutamide or abiraterone.

This description comes directly from the study's public registry record.

Talk to the study team

Amgen Call Center · 866-572-6436 · medinfo@amgen.com

Always discuss trial participation with your own doctor first.

Locations (16)

University of California San Francisco	San Francisco, California, United States	Recruiting
Dana Farber Cancer Institute	Boston, Massachusetts, United States	Recruiting
University of Minnesota	Minneapolis, Minnesota, United States	Recruiting
Cleveland Clinic Foundation	Cleveland, Ohio, United States	Recruiting
Thomas Jefferson University	Philadelphia, Pennsylvania, United States	Recruiting
University of Pittsburgh Medical Center Hillman Cancer Center	Pittsburgh, Pennsylvania, United States	Recruiting
South Texas Accelerated Research Therapeutics - Carolinas	Myrtle Beach, South Carolina, United States	Recruiting
Sarah Cannon Research Institute	Nashville, Tennessee, United States	Recruiting
Chris OBrien Lifehouse	Camperdown, New South Wales, Australia	Recruiting
Calvary Mater Newcastle Hospital	Waratah, New South Wales, Australia	Recruiting
Cabrini Hospital	Clayton, Victoria, Australia	Recruiting
Peter MacCallum Cancer Centre	Melbourne, Victoria, Australia	Recruiting

+ 4 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07140900